Cargando…
Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
INTRODUCTION: Patients with thrombocytopenia and chronic liver disease are at increased risk of bleeding during invasive procedures due to low platelet counts. Lusutrombopag, an orally active thrombopoietin receptor agonist, increases platelet count and reduces the need for platelet transfusion in c...
Autores principales: | Flamm, Steven L., Peck-Radosavljevic, Markus, Fukuhara, Takahiro, Bentley, Roy, Katsube, Takayuki, Ochiai, Toshimitsu, Kano, Takeshi, Tsukimura, Eri, Sasaki, Ritsue, Osaki, Yukio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402490/ https://www.ncbi.nlm.nih.gov/pubmed/35904722 http://dx.doi.org/10.1007/s12325-022-02237-8 |
Ejemplares similares
-
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
por: Brown, Robert S., et al.
Publicado: (2021) -
A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018) -
Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Katsube, Takayuki, et al.
Publicado: (2019) -
Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021) -
Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
por: Katsube, Takayuki, et al.
Publicado: (2020)